 |
| BHRT Up 19% On Strong Volume |
|
 Hot Stock to Watch |
Company: Bioheart Inc. (OTCQB: BHRT)
|
Last:
Price: 0.031
Change (%): + 0.005 (19.23)
Volume: 5,905,281 |
 |
Bioheart Announces World's First Combination Stem Cell Treatment
SUNRISE, FL-(Marketwired - Jul 24, 2014) - Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world’s first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell™ or adipose derived stem cells and MyoCell® or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath® Catheter.
The patient was treated at the Honduras Medical Center (http://www.hmc.com.hn/index.php?page=main) with Managing Director Dr. Ricardo Aguilar. The procedure was led by cardiologists Dr. Haroldo Lopez and Dr. Raul Marenco.
Kristin Comella, Bioheart’s Chief Scientific Officer, attended the case and said, “We are bringing new regenerative therapies to many patients around the world. We believe that this new method of cell combination is the best therapy available to patients suffering from heart failure.”
“Magnum has brought cutting edge regenerative therapies to Honduras,” said Dr. Rene Fiallos, Magnum’s Chief Medical Officer. “We are seeing excellent results so far with stem cell therapy and we are thrilled to expand our services.”
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
